Figure 5.

Neutralizing IL-17A reduces parietal cell atrophy and SPEM. TxA23 mice were treated biweekly with αIL-17A beginning at 4 weeks and concluding at 8 weeks of age. (A) Representative H&E and immunofluorescently stained sections show decreased parietal cell atrophy and SPEM in the stomachs of anti-IL-17A–treated mice compared with control TxA23 mice. Immunofluorescent sections stained with Hoechst (blue), anti-CD44v9 (red), and anti–VEGF-B (green). (B) Scoring individual stomachs for the degree of atrophy showed significantly less atrophy in treated mice compared with control mice. Each dot represents 1 mouse combined from 4 separate experiments, 7–11 mice per group. Significance was determined using a Mann–Whitney U test. (C) Quantification of SPEM+ (CD44v9+) glands in control and IL-17A-neutralized mice. Each dot represents the percentage of positive glands in 3 representative images from 1 mouse. Significance was calculated using the Student t test.